Immunogenicity Testing In Gene Therapy: What Sponsors Get Wrong When Selecting A CRO

Immunogenicity assessment in gene therapy is far more complex than in conventional biologics, yet many sponsors still evaluate CROs as though they’re sourcing a standard ADA testing package. That mismatch becomes visible only when screening assays misclassify patients, validation work stalls, or post‑dose signals can’t be interpreted with confidence. Gene therapy programs must address pre‑existing immunity, responses to capsid, promoter, and transgene components, and T‑cell activity—all of which require diverse platforms, deeper scientific judgment, and more nuanced regulatory interpretation than traditional ligand binding assays can provide.

This landscape demands a CRO that operates as a scientific partner, not just a sample processor. Effective collaboration includes co‑developing assays, navigating less‑prescriptive FDA guidance, building statistically defensible cut points, and anticipating matrix‑related challenges across unconventional sample types. It also requires technical breadth: ddPCR for biodistribution context, ELISpot and intracellular cytokine staining for T‑cell work, and reproducible NAb assays that protect enrollment integrity.

The most common selection mistakes—overweighting LBA experience, underestimating scientific engagement, and decoupling immunogenicity from the broader bioanalysis strategy—create risks that surface late and are costly to correct. Choosing a partner with true CGT‑specific expertise ensures immunogenicity results meaningfully support safety, dosing, and regulatory progress.